503B Bulks List: Semaglutide and Tirzepatide Explained

Is the FDA banning compounded semaglutide and tirzepatide?

No — not with this notice, and not yet. The honest answer has three parts, and all three matter.

What is the 503B bulks list, in plain English?

It's a federal permission list for larger-scale compounding facilities. Section 503B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353b) governs FDA-registered “outsourcing facilities” — bigger compounding operations that can make batches without a named patient on every order. These facilities can legally compound a drug from a bulk drug substance (a raw active ingredient) only if that substance appears on FDA's clinical-need list or if the finished drug is currently on FDA's national drug shortage list.

The statute uses the word “or” to join those two doors — which is why a proposed “no” on the bulks list doesn't erase the shortage door entirely.

Are semaglutide and tirzepatide on the 503B bulks list right now?

No. FDA states that neither drug currently appears on the 503B bulks list, and neither is on FDA's drug shortage list. Here's the timeline of how we got here.

What The RX Index actually verified for this page

• • The Federal Register document type (a notice), its docket, and citation.
• • The current comment deadline (July 30, 2026), including the earlier June dates it replaced.
• • The current 503B bulks list and drug shortage list status for both drugs.
• • The exact statutory text showing two separate 503B doors.
• • FDA's April 1, 2026 policy language on “significant difference,” the vitamin B12 example, and the “four or fewer prescriptions” enforcement position.

What we did not verify: whether any individual reader's specific prescription, pharmacy, formulation, or state-law situation meets every applicable requirement. That's a conversation for your prescriber, pharmacy, or a health-law attorney.

Why is the coverage so confusing — and which deadline is real?

Because the headlines mixed up five different things, and the early dates didn't match. Words like “removed,” “excluded,” “banned,” “proposed,” and “permanent” describe very different realities. On top of that, FDA's press release and its original Federal Register notice gave different June dates, and FDA later granted one formal extension. The date that controls today is July 30, 2026.

Here's where the date confusion came from:

The RX Index 503B Claim Check: what the headlines get wrong

Dataset version RXI-503B-2026-07-15. We compared common public claims against the Federal Register notice, the June 26 extension, FDA's April 1, 2026 compounding clarification, and the text of 21 U.S.C. § 353b.

We're not fact-checking other writers to be clever. We're doing it because being wrong about this can cost you money, waste a doctor's appointment, or push you toward a sketchy seller. Precision here is the whole point.

Why did FDA preliminarily say there's “no clinical need”?

“Clinical need” is a specific legal test, not a finding that no one could ever benefit from a compounded medicine. FDA's method asks one or both threshold questions as applicable. For semaglutide and tirzepatide, FDA found the first threshold unmet — and so it did not reach the second. Cost, convenience, and supply problems are left out of this test on purpose.

In the notice, FDA worked through the arguments people submitted — oral, sublingual, buccal, and injectable versions; different strengths and slower dose ramps; ingredient concerns; and combination products. Its preliminary conclusion was that the nominations didn't establish that an attribute of the FDA-approved products made them medically unsuitable for identified patients in a way the proposed compounded products would address.

That last point deserves honesty rather than spin. If you can't afford brand-name treatment, that's a genuine barrier. FDA's position isn't that your budget doesn't matter — it's that affordability, by itself, isn't what the 503B “clinical need” standard measures. The fix for cost lives in insurance, savings programs, and pricing — not in this list.

503A vs. 503B: what's the difference for GLP-1 patients?

Section 503A is a state-licensed pharmacy (or a physician) compounding for a specific, identified patient. Section 503B is a bigger FDA-registered facility making larger batches under federal manufacturing rules. This proposal targets the 503B bulks list. The separate 503A rules — especially the ban on making “essentially a copy” of an available drug — still apply on their own.

Sources: 21 U.S.C. § 353a; 21 U.S.C. § 353b; FDA Apr 1, 2026.

Does adding B12 or another ingredient make a compounded product allowed?

No — not on its own. FDA gave a specific example: a compounded product combining semaglutide with vitamin B12 (cyanocobalamin) may still be treated as “essentially a copy” of an available drug when the product is given the same way (say, by injection) and the amounts of each ingredient are within 10% of the strengths of the commercially available products. So “we added a vitamin” isn't a magic legal switch, and that specific 10% example is about B12 — don't assume it applies the same way to B6 or anything else without a separate source.

There is a separate path: FDA says a product isn't “essentially a copy” if a prescriber “determines and documents” that a change produces a significant difference for a specific, identified patient. But that's a real clinical judgment your prescriber has to make and write down for you — not a blanket rule, and not something a marketing page can promise.

Is “four or fewer prescriptions a month” a loophole?

No. Under section 503A, FDA has said that, “at this time,” it does not intend to take action on the “regularly or in inordinate amounts” condition when a compounder fills four or fewer prescriptions of that product in a calendar month. Read that carefully: it's an enforcement position — what FDA currently intends to do — not a statutory safe harbor, a license, or a promise it won't act on other problems (like a product being low-quality or unsafe). It can also change. Treat it as a caution light, not a green light.

Could 503B compounding come back during a future shortage?

Under the statute as it stands today, yes — the shortage door is separate and stays in the law. A final decision not to include semaglutide or tirzepatide on the 503B bulks list would settle the “clinical need” door against them. It would not erase the separate clause that lets 503B compounding happen when the finished drug is on FDA's shortage list. That said, no one can promise a future shortage will happen, and shortage status doesn't waive the other 503B rules.

The statute (21 U.S.C. § 353b(a)(2)) lists the two doors and joins them with the word “or”: the bulk substance is on the clinical-need list, or the finished drug is on the shortage list at the time it's compounded, distributed, and dispensed. A notice about the first door doesn't rewrite the second.

Is my compounded semaglutide or tirzepatide illegal?

There's no honest one-size-fits-all yes or no. Whether a specific compounded product is permissible depends on facts this page can't see: 503A vs. 503B, whether there's a named-patient prescription, whether bulk substances were used, current shortage status, the form and strength, what your prescriber documented, your state's rules, and other federal requirements.

This explainer summarizes public federal sources and is not legal advice. A pharmacy, prescriber, or health-law attorney who has your actual facts is far better positioned to judge a specific arrangement.

How can I tell if my pharmacy is 503A or 503B?

Start with the exact legal name and address printed on your medication label, then check whether that exact facility appears in FDA's public list of registered outsourcing facilities. A match confirms FDA listed that facility's 503B registration as complete for its latest weekly update. No match does not prove it's a 503A pharmacy — verify the name and address, check your state board, and ask the dispenser directly.

Here's why this five-minute check is worth it: FDA has flagged fraudulent compounded semaglutide and tirzepatide with false label information — in some cases naming pharmacies that don't exist, and in others naming a real, licensed pharmacy that didn't actually make the product.

Official FDA tool. A registry match only tells you a facility is registered, as of the date shown — not that any specific medication is legal, safe, FDA-approved, or compliant.

What should I do right now if I use compounded semaglutide or tirzepatide?

Don't stop, switch, ration, or stockpile your medication just because of a headline. Identify your pharmacy, save your label and packaging, and talk to your prescriber about the clinical basis and a continuity plan before you change anything. This is a moment for calm verification, not panic.

FDA adverse-event context: As of May 31, 2026, FDA had received 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide. FDA notes many mirror the side effects seen with the approved drugs, causation isn't always clear, and reporting is likely incomplete. None of that means compounded medicine is automatically dangerous — it means verify your source and don't improvise your dosing.

What happens next with FDA's 503B proposal?

FDA is taking public comments through July 30, 2026, unless it changes the schedule again. After that, it reviews the docket, may seek advisory-committee input, and can finalize the proposal as-is or change it before publishing a final Federal Register determination. The notice sets no fixed final-decision date.

FDA asks commenters to support their position and address the factors in its clinical-need analysis. If you want to comment, go straight to the official docket (FDA-2018-N-3240) on Regulations.gov. Two honest cautions: public comments can be posted publicly, so don't include private medical details — FDA's extension notice specifically warns against putting confidential information in a submission — and comment volume alone doesn't decide the outcome.

What treatment paths are left if my supply changes?

Your options depend on your diagnosis, state, insurance and formulary, preferred form, budget, and your clinician's judgment. They generally fall into three buckets. We'll keep FDA-approved and compounded options strictly separate, because they are not the same thing.

FDA-approved medication (through insurance or cash-pay)

This is the path with the most regulatory certainty, because these medications went through FDA's full review for safety, effectiveness, and quality. Cash-pay pricing has also come down a lot.

This is one factual example of an FDA-approved treatment path, not a claim that Ro is best for every reader.

Patient-specific 503A compounding

Patient-specific 503A compounding may remain available when the prescription satisfies the applicable federal and state conditions. A prescriber's or pharmacy's judgment alone doesn't establish compliance — which is why the verification steps above matter. If you think a customized formulation is genuinely right for you, our tool can help you narrow legitimate options and prompt the right questions before you commit.

Other clinician-directed paths

Your clinician might also discuss another FDA-approved medication, a non-GLP-1 option, a different strategy, or lifestyle and behavioral support — or pausing treatment if that's medically right. Those are decisions for you and your clinician, not for a web page to rank.

Whichever bucket fits, the fastest way to see your specific options is our matching tool. Find My GLP-1 Path →

How we researched this page

The RX Index Editorial Team used the U.S. Code, the Federal Register, FDA policy pages, FDA's Drug Shortages Database, and FDA's outsourcing-facility registry as the controlling sources. Secondary coverage was used only to identify claims worth checking and patient questions worth answering — not to establish regulatory or medical facts. Prices and provider details are dated and traceable to the source; medication decisions belong with your clinician.

What are the most common questions about the 503B bulks list and GLP-1 compounding?

The questions below settle the issues that most often send people back to searching: whether the proposal is final, how 503A differs from 503B, what additives change, whether a future shortage matters, and what current patients should do. Each answer summarizes the primary-source analysis above — it is not a verdict on an individual prescription.